| Obesity
Foundayo vs Saxenda
Side-by-side clinical, coverage, and cost comparison for obesity.Deep comparison between: Foundayo vs Saxenda with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSaxenda has a higher rate of injection site reactions vs Foundayo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Saxenda but not Foundayo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Foundayo
Saxenda
At A Glance
Oral
Daily
GLP-1 receptor agonist
SC injection
Daily
GLP-1 receptor agonist
Indications
- Obesity
- Obesity
- Overweight and obesity
Dosing
Obesity Start at 0.8 mg orally once daily; escalate to 2.5 mg, then 5.5 mg, then optionally to 9 mg, 14.5 mg, or 17.2 mg (maximum) once daily, increasing at intervals of at least 30 days based on tolerability; take with or without food; swallow tablets whole.
Obesity, Overweight and obesity Initiate at 0.6 mg SC once daily; escalate weekly to recommended dose of 3 mg SC once daily in abdomen, thigh, or upper arm; pediatric maintenance dose may be reduced to 2.4 mg daily if 3 mg not tolerated.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
- Known serious hypersensitivity to orforglipron or any excipient in FOUNDAYO
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity reaction to liraglutide or any excipient in SAXENDA
Adverse Reactions
Most common (>=5%) Nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, hair loss
Serious Thyroid C-cell tumors, acute pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, pulmonary aspiration, acute renal failure or worsening of chronic renal failure sometimes requiring hemodialysis
Most common (>=2%) Nausea, diarrhea, constipation, vomiting, injection site reaction, headache, hypoglycemia in T2DM, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, gastroenteritis, gastroesophageal reflux disease, abdominal distension, eructation, flatulence
Serious Thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, hypoglycemia with concomitant anti-diabetic therapy, heart rate increase, acute kidney injury due to volume depletion, severe gastrointestinal reactions, hypersensitivity reactions including anaphylaxis, pulmonary aspiration
Postmarketing Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, hyperbilirubinemia, cholestasis, hepatitis, angioedema, anaphylactic reactions, medullary thyroid carcinoma, acute kidney injury, cutaneous amyloidosis, alopecia
Pharmacology
Orforglipron is a small-molecule GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor, reducing appetite and caloric intake by activating GLP-1 receptors in brain regions that regulate appetite and food intake, and also delays gastric emptying.
Liraglutide is an acylated human GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37) that binds and activates the GLP-1 receptor to reduce calorie intake and lower body weight; it also stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Foundayo
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (0/12) · Qty limit (0/12)
Saxenda
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Foundayo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Saxenda
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Foundayo
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Saxenda
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$149/momo
Foundayo Self-Pay Savings Card ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Saxenda.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FoundayoView full Foundayo profile
SaxendaView full Saxenda profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.